← All sessions

MedTech Leading Voice · 22 Sept 2026

FDA Ground Truth 2026

Steve Silverman and the panel review CDRH changes, QMSR, MDUFA VI and inspection risk for medtech professionals.

Plays from YouTube when you press play. Cookie settings

What the session covered

The session examined how medtech regulatory professionals should read the current FDA landscape, with a focus on CDRH rather than leadership churn in the commissioner's office. Steve Silverman set out changes over 18 months, including QMSR, the RAPID pilot, guidance output, MDUFA commitments and slower authorisation times, and generative AI. Phil and David discussed the 2025 reduction in force, estimated at roughly 20 to 24 per cent of CDRH resources, its effect on review detail and morale, and early signs of hiring and stabilisation. Michelle covered QMSR misconceptions, the limits of ISO 13485 alignment, risk-based approach, culture of quality, management review, complaints and the medical device file. Jeff added small company concerns. The panel discussed inspection trends, risk as a top observation, 483 remediation across QSR and QMSR, MDUFA VI pre-submission changes including a proposed $2,000 fee, and practical use of pre-submissions and 513(g)s. The viewer takeaway is that CDRH is meeting many MDUFA timing goals but capacity and review substance remain under strain, so companies should document defensible regulatory positions, use informal FDA contact carefully, and prepare for QMSR and risk expectations.

Figures

Figures the speakers cited

2,200CDRH resources at the end of 2024
23%CDRH resource reduction cited by Dr. Tarver
20–24%range of CDRH resource reduction estimates
about 25new hires in CDRH's first hiring class
110 pageslength of the QMSR publication
100 pagesportion of the QMSR publication devoted to comments and expectations
4,000+pre-submissions per year
$2,000new fee for most pre-submissions under MDUFA 6
$12,000first-year annual facility fee for a U.S. facility under MDUFA 6
$17,000first-year annual facility fee for a non-U.S. facility under MDUFA 6

Source: Bill Desjardins

Chapters

Jump to a moment

  1. Housekeeping, polls, and speaker introductions
  2. Steve Silverman on recent FDA and CDRH changes
  3. CDRH staffing cuts and their effect on review depth
  4. QMSR: ISO 13485 gaps, risk, management review, and the medical device file
  5. Risk-based approach, 483 trends, and inspection experience
  6. MDUFA 6: fees, pre-sub changes, and hiring commitments
  7. What makes a useful pre-submission

Times run from the start of the recording.

Take these with you

Six checks

Audit your QMSR gap listCheck the four or five QMSR sections FDA did not fully harmonize with ISO 13485.
Treat management review as a system testMake sure CAPA, complaint, supplier, and audit signals roll up into management review.
Define the medical device fileState in your quality manual or design procedures that the DHF and DMR are now the medical device file.
Clarify the purpose before filing a pre-subDecide what specific decision or feedback you need before spending time or the new $2,000 fee.
Track review depth, not just MDUFA clocksWatch whether additional-information letters give enough detail for deficiencies two and three.
Plan for MDUFA 6 facility feesModel the first-year facility fee changes for U.S. versus non-U.S. sites.

Full recording

83:19

Plays from YouTube when you press play. Cookie settings

How to cite this session

Sean, Silverman, S., Lott, M., Fillmore, D., Desjardins, B., Lips, J. (2026, September 22). FDA Ground Truth 2026 [Webinar]. MedTech Leading Voice, MedTech Leading Voice. medtechleadingvoice.com/watch/2026-09-22-fda-ground-truth-2026

Earlier sessions

6 Nov 2026Methodological Quality and Scientific Validity Under the MDR 30 Oct 2026AI Pre-Submission Review Under the MDR 29 Oct 2026Your commercial training is part of HF validation

Latest issues

Issue 189MDR and IVDR Evidence Requirements in Transition Issue 188Industry Groups Back a Single Regulatory Pathway for AI-Enabled Medical Devices Issue 187The First Long-Term Pacemaker Implant Happened in Uruguay